Aradigm Corp., of Hayward, Calif., appointed Bryan Lawlis chief operating officer and said Babatunde Otulana, its vice president for clinical and regulatory affairs, was appointed to serve on the FDA¿s Anesthesiology and Respiratory Therapy Devices panel as a non-voting industry representative.
Bionomics Ltd., of Adelaide, Australia, appointed Gabriel Kremmidiotis head of bioinformatics and Francis Placanica vice president of business development.
BioTransplant Inc., of Charlestown, Mass., appointed Barbara Wallner chief scientific officer.
Celgene Corp., of Warren, N.J., elected Robert Hugin to its board.
Cell Therapeutics Inc., of Seattle, added Vartan Gregorian to its board.
Cetek Corp., of Marlborough, Mass., promoted James Little to president; Dallas Hughes to senior vice president, technology; and Herbert Hedberg to senior vice president, operations.
Corus Pharma Inc., of Seattle, named Kirby Cramer to its board.
CuraGen Corp., of New Haven, Conn., elected Ronald Cresswell to its board.
CytoGenix Inc., of Houston, added Alan Gewirtz to its scientific advisory board.
Deltagen Inc., of Redwood City, Calif., appointed Majid Mehtali scientific director of Deltagen Europe SA.
Discovery Laboratories Inc., of Doylestown, Pa., appointed John Cooper senior vice president, chief financial officer.
Diversa Corp., of San Diego, appointed Lisa Moss senior director of pharmaceutical business development, Mick Noordewier senior director of bioinformatics, Bruce Kimmel director of protein therapeutics and Geoffrey Hazlewood director of industrial enzyme products. Also, the company promoted Mervyn Bibb to senior director, small molecule discovery, and Mike Lafferty to director, engineering technology.
Diversys Ltd., of Cambridge, UK, added Montgomery Mars as chief financial officer and general manager of its proteomics business unit.
DOR BioPharma Inc., of Chicago, added Colin Bier, Peter Kliem and Guy Rico to its board.
Dyax Corp., of Cambridge, Mass., appointed Anthony Williams senior vice president, medical affairs and clinical operations and Lynn Baird senior vice president, preclinical and regulatory affairs.
Esperion Therapeutics Inc., of Ann Arbor, Mich., added Susan Bayh and Ronald Cresswell to its board.
Feinstein Kean Healthcare, of Cambridge, Mass., added Michael Lampe as director in its marketing and scientific communications practice.
Forward Ventures, of San Diego, added Joel Martin as a partner.
Gemin X Biotechnologies Inc., of Montreal, appointed Giorgio Attardo director of medicinal chemistry.
Genelabs Technologies Inc., of Redwood City, Calif., appointed Ronald Griffith vice president of research.
Genmab A/S, of Copenhagen, Denmark, appointed Rachel Gravesen vice president, public and investor relations.
GenoMed Inc., of St. Louis, added Tony Frudakis to its scientific advisory board and Richard Kranitz as corporate secretary and a member of its board.
Genta Inc., of Berkeley Heights, Calif., appointed Patrick Zenner to its board.
ICN Pharmaceuticals Inc., of Costa Mesa, Calif., appointed Marinko Vekovic senior vice president, worldwide corporate sales and marketing.
Iconix Pharmaceuticals Inc., of Mountain View, Calif., appointed Leslie Browne chief operating officer.
Immusol Inc., of San Diego, added Michael Sherman as vice president, medical and clinical affairs.
Innate Pharma SAS, of Marseille, France, appointed Philippe Pouletty and Bernard Malissen to its board.
Innovadyne Technologies Inc., of Santa Rosa, Calif., named Joel McComb CEO, adding to his role as president.
Integrative Proteomics Inc., of Toronto, appointed Molly Schmid senior vice president, antibacterial pharmaceuticals and alliances.